The estimated Net Worth of James S. Hanson is at least $5.22 Milión dollars as of 3 January 2023. Mr. Hanson owns over 2,368 units of G1 Therapeutics Inc stock worth over $292,950 and over the last 6 years he sold GTHX stock worth over $28,403. In addition, he makes $4,898,580 as General Counsel a Secretary at G1 Therapeutics Inc.
Sign up
Mr. Hanson GTHX stock SEC Form 4 insiders trading
James has made over 5 trades of the G1 Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,368 units of GTHX stock worth $13,071 on 3 January 2023.
The largest trade he's ever made was selling 2,368 units of G1 Therapeutics Inc stock on 3 January 2023 worth over $13,071. On average, James trades about 757 units every 165 days since 2018. As of 3 January 2023 he still owns at least 41,087 units of G1 Therapeutics Inc stock.
You can see the complete history of Mr. Hanson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Hanson biography
James Stillman Hanson J.D. serves as General Counsel, Secretary of the Company. Mr. Hanson served as Associate General Counsel and Vice President at IQVIA, a publicly traded healthcare services company from October 2016 to June 2018. Mr. Hanson served as Associate General Counsel at Quintiles Holdings Inc., or Quintiles, from November 2010 to October 2016, when Quintiles merged with IMS Health. Before joining Quintiles in 2010, Mr. Hanson practiced corporate law at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP, a Raleigh, North Carolina law firm. Mr. Hanson is admitted to the North Carolina state bar.
What is the salary of James Hanson?
As the General Counsel a Secretary of G1 Therapeutics Inc, the total compensation of James Hanson at G1 Therapeutics Inc is $4,898,580. There are 1 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.
How old is James Hanson?
James Hanson is 48, he's been the General Counsel a Secretary of G1 Therapeutics Inc since 2018. There are 19 older and 6 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.
What's James Hanson's mailing address?
James's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.
Insiders trading at G1 Therapeutics Inc
Over the last 8 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman a Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
What does G1 Therapeutics Inc do?
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
What does G1 Therapeutics Inc's logo look like?
Complete history of Mr. Hanson stock trades at G1 Therapeutics Inc
G1 Therapeutics Inc executives and stock owners
G1 Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Avagliano,
Chief Business Officer -
James Hanson,
General Counsel, Secretary -
Mark Velleca,
President, Chief Executive Officer, Director -
Terry Murdock,
Chief Operating Officer -
Garry Nicholson,
Independent Chairman of the Board -
Jennifer Moses,
Chief Financial Officer -
Rajesh Malik,
Chief Medical Officer, Senior Vice President - Research and Development -
Dr. Mark A. Velleca M.D., Ph.D.,
Sr. Advisor & Director -
Mark Avagliano,
Chief Bus. Officer -
Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
Chief Medical Officer and Sr. VP of R&D -
Dr. Rajesh K. Malik,
Chief Medical Officer and Sr. VP of R&D -
Andrew Perry,
Chief Commercial Officer -
Jennifer K. Moses CPA,
Chief Financial Officer -
Jennifer K. Moses,
Chief Financial Officer -
Seth Rudnick,
Independent Director -
Glenn Muir,
Independent Director -
Cynthia Schwalm,
Independent Director -
Fredric Eshelman,
Independent Director -
Willie Deese,
Independent Director -
Andrew Witty,
Independent Director -
John Bailey,
Independent Director -
Soma Gupta,
Chief Commercial Officer -
Jay Strum,
Chief Scientific Officer -
Terry L. Murdock,
Chief Operating Officer -
Blake Jensen,
VP of Quality & Compliance -
William C. Roberts,
VP of Investor Relations & Corp. Communications -
Dr. Jay C. Strum,
Chief Scientific Officer -
Alexander D. Smith M.S.,
VP of Technical Operations -
John E. Bailey Jr.,
CEO, Pres & Director -
Clay Hatteras Venture Advis...,
-
Capital Management, L.P.Ra ...,
-
Christy L Shaffer,
Director -
Ventures, Inc. Med Immune,
10% owner -
Ventures, Llc Eshelman,
10% owner -
Clay Hatteras Venture Advis...,
-
Barclay A Phillips,
SVP & Chief Financial Officer -
Monica R. Thomas,
Chief Legal & People Officer -
Jacks Lee,
-
John Demaree,
Chief Commercial Officer -
Alicia Secor,
-
Cynthia Louise Flowers,
-
Andrew Perry,
Chief Commercial Officer -
Norman Sharpless,
-
John W. V Umstead,
Chief Financial Officer